Rationale and design of the Lead Evaluation for Defibrillation and Reliability study: Safety and efficacy of a novel ICD lead design. (8th January 2023)

• Record Type: Journal Article
• Authors: Crossley, George H.; Sanders, Prashanthan; De Filippo, Paolo; Tarakji, Khaldoun G.; Hansky, Bert; Shah, Maully; Mason, Pamela; Maus, Baerbel; Holloman, Keith
• Is Part Of: Journal of cardiovascular electrophysiology. Volume 34:Number 2(2023)
• Page Start: 257
• Page End: 267
• Publication Date: 2023-01-08
• Subjects: adaptive design -- defibrillation lead -- virtual patient modeling; Blood vessels -- Physiology -- Periodicals; Electrophysiology -- Periodicals; Heart -- Physiology -- Periodicals; 612.1
• DOI: 10.1111/jce.15747
• Languages: English
• ISSNs: 1045-3873

Abstract

Abstract: Background: Implantable cardioverter defibrillators (ICD) are indicated for primary and secondary prevention of sudden cardiac arrest. Despite enhancements in design and technologies, the ICD lead is the most vulnerable component of the ICD system and failure of ICD leads remains a significant clinical problem. A novel, small‐diameter, lumenless, catheter‐delivered, defibrillator lead was developed with the aim to improve long‐term reliability. Methods and Results: The Lead Evaluation for Defibrillation and Reliability (LEADR) study is a multi‐center, single‐arm, Bayesian, adaptive design, pre‐market interventional pivotal clinical study. Up to 60 study sites from around the world will participate in the study. Patients indicated for a de novo ICD will undergo defibrillation testing at implantation and clinical assessments at baseline, implant, pre‐hospital discharge, 3 months, 6 months, and every 6 months thereafter until official study closure. Patients may be participating for a minimum of 18 months to approximately 3 years. Fracture‐free survival will be evaluated using a Bayesian statistical method that incorporates both virtual patient data (combination of bench testing to failure with in‐vivo use condition data) with clinical patients. The clinical subject sample size will be determined using decision rules for number of subject enrollments and follow‐up time based upon the observed number of fractures at certain time points in the study. The adaptive study design will therefore result in a minimum of 500 and a maximum of 900 patients enrolled. Conclusion: The LEADR Clinical Study was designed to efficiently provide evidence for short‐ and long‐term safety and efficacy of a novel lead design using Bayesian methods including a novel virtual patient approach. Abstract : The design of the LEADR study is presented. This studies a novel ICD lead that is built on the robust design of the existing Medtronic Model 3830 lead. Both have a flexible central conductor which is designed to make the lead more reliable.